Research Article

Biomarkers in Enteropathic Arthritis

Luis Arturo Gutiérrez-Gonzalez*, Eillen Macias, Freddy Herrera-Vivas, Franz Otaiza, Juan Carlos Gonzalez Duran and Guillermo Veitia

Published: 04 June, 2020 | Volume 4 - Issue 1 | Pages: 039-044

Inflammatory Bowel Disease (IBD)-associated arthritis is called Enteropathic Arthritis (EA) which is classified among the group of Spondyloarthritis (SpA), because its presentation is variable. The current trend is to classify them as autoinflammatory rather than autoimmune diseases, since no antibodies have yet been identified. The study of biomarkers (BM) will help us with early identification and hence, to provide treatment in the early stages, prior to radiographic progression, which will enable prompt identification of the disease phenotype. 42 patients diagnosed with IBD were included, of which 48% were females; the mean age of the study group was 48.12 ± 5.02 (95% CI). The average time of evolution of disease was 37.57 ± 14.28 months; most patients referred to the rheumatologist had a diagnosis of ulcerative colitis (83%). According to our analysis, we were able to determine that the three most significant variables influencing the development of sacroiliitis were: Lactoferrin, ANCA and HLA B27 (p < 0.5). The variable that can be ruled out because of its almost neglectable contribution was fecal calprotectin.

Read Full Article HTML DOI: 10.29328/journal.acgh.1001021 Cite this Article Read Full Article PDF


Biomarkers; Spondyloarthritis; Inflammatory Bowel Disease; ASCA; ANCA; HLAB-27


  1. Bossuyt X. Serologic markers in inflammatory bowel disease. Clin Chem. 2006; 52: 171-181. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16339302
  2. Sandborn WJ. Serologic markers in inflammatory bowel disease: state of the art. Rev Gastroenterol Disord. 2004; 4: 167-174.
  3. Prideaux L, De Cruz P, Ng SC, Kamm MA. Serological antibodies in infl ammatory bowel disease: a systematic review. Infl amm Bowel Dis. 2012; 18: 1340-1355. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22069240
  4. Abadi I, Gonzalez L, Paul H, Grases P, Pérez G, et al. Silent colonic findings in seronegative spondyloarthropathies. Rev Rheumat. 1981; 11: 119.
  5. Dougados M, Van der Linden S, Juhlin R, Huitfeldt B, Amor B, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 1991; 34: 1218-1227.
  6. Saxon A, Shanahan F, Landers C, Ganz T, Targan S. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol. 1990; 86: 202-210. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/2200820
  7. Rump JA, Scholmerich J, Gross V, Roth M, Helfesrieder R, et al. A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn’s disease. Immunobiology. 1990; 181: 406–413. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/2099908
  8. Zhou G, Song Y, Yang W, Guo Y, Fang L, et al. ASCA, ANCA, ALCA and Many More: Are They Useful in the Diagnosis of Inflammatory Bowel Disease?. Dig Dis. 2016; 34: 90-97.
  9. Homsak E, Micetic-Turk D, Bozic B. Autoantibodies pANCA, GAB and PAB in infl ammatory bowel disease: prevalence, characteristics and diagnostic value. Wien Klin Wochenschr. 2010; 122(Suppl 2): 19-25. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20517666
  10. Rudwaleit M, Baeten D. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol. 2006; 20: 451-471. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16777576
  11. Austin GL, Herfarth HH, Sandler RS. A critical evaluation of serologic markers for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007; 5: 545-547. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17433787
  12. Desplat-Jégo S, Johanet C, Escande A, Goetz J, Fabien N, et al. Update on anti-Saccharomyces cerevisiae antibodies, anti-nuclear associated anti-neutrophil antibodies and antibodies to exocrine pancreas detected by indirect immunofluorescence as biomarkers in chronic inflammatory bowel diseases: Results of a multicenter study, World J Gastroenterol. 2007; 13: 2312-2318. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17511029
  13. Austin GL, Shaheen NJ, Sandler RS. Positive and negative predictive values: Use of inflammatory bowel disease serologic markers. Am J Gastroenterol. 2006; 101: 413-416. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16542272
  14. Mendoza JL, Abreu MT. Biological markers in inflamatory bowel disease: Practical consideration for clinicians. Gastroenterol Clin Biol. 2009; 33(Suppl 3): S158-173. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20117339
  15. Reumaux D, Sendid B, Poulain D, Duthilleul P, Dewit O, et al. Serological markers in inflammatory bowel diseases. Best Pract Res Clin Gastroenterol. 2003; 17: 19–35. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3900099/
  16. Danese S, Papa A, Saibeni S, Repici A, Malesci A, et al. Inflammation and coagulation in inflammatory bowel disease: The clot thickens. Am J Gastroenterol. 2007; 102: 174-186. PubMed:  https://www.ncbi.nlm.nih.gov/pubmed/17100967
  17. Paredes JM, Barrachina MM, Roman J, Moreno-Osset E. Patología articular en la enfermedad inflamatoria intestinal. Gastroenterol Hepatol. 2005; 28: 240-249.
  18. Danese S, Semeraro S, Papa A, Roberto I, Scaldaferri F, et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol. 2005; 11: 7227-7236. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16437620
  19. Aydin SZ, Maksymowych WP, Bennett AN, McGonagle D, Emery P, et al. Validation of the ASAS criteria and definition of a positive MRI of the sacroiliac joint in an inception cohort of axial spondyloarthritis followed up for 8 years. Ann Rheum Dis. 2012; 71: 56-60. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21900284
  20. Weber U, Lambert RGW, Østergaard M, Hodler J, Pedersen SJ, et al. The diagnostic utility of magnetic resonance imaging in spondyloarthritis. An international multicenter evaluation of one hundred eighty-seven subjects. Arthritis Rheum. 2010; 62: 3048-3058. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20496416
  21. Conigliaro P., et al. Impact of a multidisciplinary approach in enteropathic spondyloarthritis patients. Autoimmunity Reviews. 2016 Feb;15(2):184-90.
  22. Gutierrez-Gonzalez LA, Nuñez-Sotelo CM, Gonzalez N, Losada BR. High level CTx-II in early Spondyloarthritis patients. Rev Argent Reumatol. 2007; 18: 2.
  23. Sarzi-Puttini, Ardizzone S, Manzionna G, et al. Infliximab-induced lupus in Crohn’s disease: a case report. Dig Liver Dis. 2003; 35: 814–817. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/14674674
  24. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, et al. ACCENT I Study Group. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002; 35: 1541–1549. PubMed: https://pubmed.ncbi.nlm.nih.gov/12047962
  25. Hanauer S, Sandborn W, Rutgeerts P, Fedorak RN, Lukas M, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006; 130: 323–333. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16472588
  26. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353: 2462–2476. PubMed: https://pubmed.ncbi.nlm.nih.gov/16339095
  27. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, et al. PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med. 2007; 357: 228–238. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17634458
  28. Kolho KL, Raivio T, Lindahl H, Savilahti E. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease. Scand J Gastroenterol. 2006; 41: 720-725. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16716972
  29. Bonnin Tomás A, Vila Vidal M, Rosell Camps A. Calprotectina fecal como marcador diferencial entre patología gastrointestinal orgánica y funcional. Rev Esp Enferm Dig. 2007; 99: 689-693.
  30. Arai R. Serologic markers: impact on early diagnosis and disease stratification in infl ammatory bowel disease. Postgrad Med. 2010; 122: 177-185. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20675980
  31. Riis L, Vind I, Vermeire S, Wolters F, Katsanos K, Politi P, et al. The prevalence of genetic and serologic markers in an unselected European population-based cohort of IBD patients. Infl amm Bowel Dis. 2007; 13: 24–32. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17206636
  32. Grzybowska-Chlebowczyk U, Wos H, Sieron AL, Wiecek S, Augusciak-Duma A, et al. Serologic investigation in children with infl ammatory bowel disease and food allergy. Mediators Inflamm. 2009; 5126195. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2796464/
  33. Basta Z, Csi I, Szabo G, Szegedi G. Seroreactovity against Saccharomyces cerevisiae in patients with Crohn’s disease and celiac disease. World J Gastroenterol. 2003; 9: 2380–2412. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4656483/
  34. Eriksson C, Engstrand S, Sundqvist KG, Rantapää-Dahlqvist S, et al. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF. Ann Rheum Dis. 2005; 64: 403–407. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15297281
  35. Nakamura RM, Matsutani M, Barry M. Advances in clinical laboratory tests for inflammatory bowel disease. Clin Chim Acta. 2003; 335: 9-20. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12927679
  36. Picchianti-Diamanti A, Lorenzetti R, Chimenti MS , Luchetti MM, Conigliaro P, et al. Enteropathic spondyloarthritis: Results from a large nationwide database analysis. Autoimmunity Reviews. 2020; 19: 102457. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31838160
  37. Beigel F, Ju¨rgens M, Tillack C, Subklewe M, Mayr D, et al. Hepatosplenic T-cell lymphoma in a patient with Crohn’s disease. Nat Rev Gastroenterol Hepatol. 2009; 6: 433–436. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19575026
  38. Talwalkar JA, Lindor KD. Primary sclerosing cholangitis. Inflamm Bowel Dis. 2005; 11: 62-72. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15674115
  39. García-Planella E, Domènech E. Osteopenia y osteoporosis en la enfermedad inflamatoria intestinal. Gastroenterol Hepatol. 2004; 27: 417-424.
  40. Mintz R, Feller ER, Bahr RL, Shah SA. Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2004; 10: 135-139. PubMed: https://pubmed.ncbi.nlm.nih.gov/15168814
  41. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol. 2006; 12: 4819- 4831. PubMed: https://pubmed.ncbi.nlm.nih.gov/16937463
  42. Storch I, Sachar D, Katz S. Pulmonary manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2003; 9: 104-115. PubMed: https://pubmed.ncbi.nlm.nih.gov/12769444
  43. Trost LB, McDonell JK. Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J. 2005; 81: 580-585. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16143688
  44. Tsianos EV, Katsanos K. Do we really understand what immunological disturbances in inflammatory bowel disease mean? World J Gastroenterol. 2009; 15: 521-555.

Similar Articles

  • Biomarkers in Enteropathic Arthritis
    Luis Arturo Gutiérrez-Gonzalez*, Eillen Macias, Freddy Herrera-Vivas, Franz Otaiza, Juan Carlos Gonzalez Duran and Guillermo Veitia Luis Arturo Gutiérrez-Gonzalez*,Eillen Macias,Freddy Herrera-Vivas,Franz Otaiza,Juan Carlos Gonzalez Duran,Guillermo Veitia. Biomarkers in Enteropathic Arthritis. . 2020 doi: 10.29328/journal.acgh.1001021; 4: 039-044
  • Systematic review and meta-analysis of drug induced liver injury secondary to biologic medications in inflammatory bowel disease
    Eyad Gadour* and Zeinab Hassan Eyad Gadour*,Zeinab Hassan. Systematic review and meta-analysis of drug induced liver injury secondary to biologic medications in inflammatory bowel disease. . 2021 doi: 10.29328/journal.acgh.1001025; 5: 005-012
  • Pattern of Clinical Presentation and Management of Inflammatory Bowel Disease
    Mohamed Abdalla Elamin Abdelgader, Abdelgadir Suliman Ibrahim, Sara Elfadel Abbas, Awadalla Abdelwahid Suliman*, Mohamed Suliman I Ahmed, Safa Mohamed Ibrahim and Abdelmoneim Altayeb Abdo Mohamed Abdalla Elamin Abdelgader, Abdelgadir Suliman Ibrahim, Sara Elfadel Abbas, Awadalla Abdelwahid Suliman*, Mohamed Suliman I Ahmed, Safa Mohamed Ibrahim, Abdelmoneim Altayeb Abdo. Pattern of Clinical Presentation and Management of Inflammatory Bowel Disease. . 2023 doi: 10.29328/journal.acgh.1001040; 7: 011-018

Recently Viewed

Read More

Most Viewed

Read More

Help ?